Antineoplastic Agents - Adverse effects
Research News and Information

Monday, November 23, 2009

Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation.

30 Oct 2009 BACKGROUND: Protecting future childbearing motivates young women with breast cancer to seek oocyte or embryo cryopreservation. Concerns about delays in cancer treatment may influence patients and practitioners considering these procedures. In this ... Read more...

Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.

20 Oct 2009 BACKGROUND: Preoperative cisplatin alone may be as effective as cisplatin plus doxorubicin in standard-risk hepatoblastoma (a tumor involving three or fewer sectors of the liver that is associated with an alpha-fetoprotein level of >100 ng per ... Read more...

Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.

18 Oct 2009 OBJECTIVE: To describe the characteristics of children enrolled in treatment trials for neurofibromatosis type 1 (NF1)-related plexiform neurofibroma (PN), PN tumor burden, PN-related complications, and treatment outcomes and to highlight the ... Read more...

Latest indexed articles for 'Antineoplastic Agents - Adverse effects'

These are the very latest articles for this heading:

• The beneficial role of gonadotropin releasing hormone agonists on fertility preservation. 29 Nov 2009
• Monitoring of ototoxicity in young children receiving carboplatin for retinoblastoma. 29 Nov 2009
• Skin depigmentation induced by sunitinib treatment of renal cell carcinoma. 30 Oct 2009
• Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. 30 Oct 2009
• Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. 20 Oct 2009
• Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. 18 Oct 2009
• Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. 13 Oct 2009
• Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. 5 Oct 2009
• Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a cumulative dose-effect analysis. 4 Oct 2009
• Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. 29 Sep 2009
• Radiochemotherapy in the elderly with lung cancer. 29 Sep 2009
• Combination of radiotherapy and chemotherapy in locally advanced NSCLC. 29 Sep 2009
• Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. 29 Sep 2009
• Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. 29 Sep 2009
• Exercise for the management of cancer-related fatigue. 29 Sep 2009
• Case of fulminant colitis after docetaxel therapy for breast carcinoma in a patient with underlying ulcerative colitis. 29 Sep 2009
• Reproductive outcomes in male childhood cancer survivors: a linked cancer-birth registry analysis. 29 Sep 2009
• Pregnancy outcomes in female childhood and adolescent cancer survivors: a linked cancer-birth registry analysis. 29 Sep 2009
• A step in the right direction, but one size might not fit all. 29 Sep 2009
• [Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC): evaluation, prevention and policies to avoid occupational exposure for operating room personnel] 29 Sep 2009

See a longer list of these articles.

Technical information about 'Antineoplastic Agents'

Definition: Substances that inhibit or prevent the proliferation of NEOPLASMS.

Registry Number: 0

Descriptor UI: D000970

Alternative terms: Antineoplastic Agents; Agents, Antineoplastic; Antineoplastics; Antitumor Drugs; Drugs, Antitumor; Antineoplastic Drugs; Drugs, Antineoplastic; Antitumor Agents; Agents, Antitumor;

Related Mesh Headings: Cytotoxins; Infusions, Intra-Arterial; Chemotherapy, Cancer, Regional Perfusion; Tumor Lysis Syndrome; Chemoembolization, Therapeutic; Anticarcinogenic Agents;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.248;

Technical Notes: /admin: various administration procedures are available, as CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CHEMOEMBOLIZATION, THERAPEUTIC and INFUSIONS, INTRA-ARTERIAL; for combined anticancer agents, ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS is available; Manual 24.4.2.1+